Your browser doesn't support javascript.
loading
Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer.
Xu, Ziyang; Walker, Susanne; Wise, Megan C; Chokkalingam, Neethu; Purwar, Mansi; Moore, Alan; Tello-Ruiz, Edgar; Wu, Yuanhan; Majumdar, Sonali; Konrath, Kylie M; Kulkarni, Abhijeet; Tursi, Nicholas J; Zaidi, Faraz I; Reuschel, Emma L; Patel, Ishaan; Obeirne, April; Du, Jianqiu; Schultheis, Katherine; Gites, Lauren; Smith, Trevor; Mendoza, Janess; Broderick, Kate E; Humeau, Laurent; Pallesen, Jesper; Weiner, David B; Kulp, Daniel W.
Afiliação
  • Xu Z; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Walker S; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Wise MC; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Chokkalingam N; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.
  • Purwar M; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Moore A; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Tello-Ruiz E; Molecular and Cellular Biochemistry, Indiana University, Bloomington, IN, 47405, USA.
  • Wu Y; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Majumdar S; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Konrath KM; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Kulkarni A; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Tursi NJ; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Zaidi FI; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Reuschel EL; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Patel I; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Obeirne A; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Du J; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Schultheis K; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Gites L; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
  • Smith T; Molecular and Cellular Biochemistry, Indiana University, Bloomington, IN, 47405, USA.
  • Mendoza J; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.
  • Broderick KE; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.
  • Humeau L; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.
  • Pallesen J; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.
  • Weiner DB; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.
  • Kulp DW; Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA.
Nat Commun ; 13(1): 695, 2022 02 04.
Article em En | MEDLINE | ID: mdl-35121758
ABSTRACT
HIV Envelope (Env) is the main vaccine target for induction of neutralizing antibodies. Stabilizing Env into native-like trimer (NLT) conformations is required for recombinant protein immunogens to induce autologous neutralizing antibodies(nAbs) against difficult to neutralize HIV strains (tier-2) in rabbits and non-human primates. Immunizations of mice with NLTs have generally failed to induce tier-2 nAbs. Here, we show that DNA-encoded NLTs fold properly in vivo and induce autologous tier-2 nAbs in mice. DNA-encoded NLTs also uniquely induce both CD4 + and CD8 + T-cell responses as compared to corresponding protein immunizations. Murine neutralizing antibodies are identified with an advanced sequencing technology. The structure of an Env-Ab (C05) complex, as determined by cryo-EM, identifies a previously undescribed neutralizing Env C3/V5 epitope. Beyond potential functional immunity gains, DNA vaccines permit in vivo folding of structured antigens and provide significant cost and speed advantages for enabling rapid evaluation of new HIV vaccines.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles Assunto principal: Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Vacinas de DNA / Produtos do Gene env do Vírus da Imunodeficiência Humana / Anticorpos Neutralizantes Limite: Animals / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles Assunto principal: Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Vacinas de DNA / Produtos do Gene env do Vírus da Imunodeficiência Humana / Anticorpos Neutralizantes Limite: Animals / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
...